0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Letters |

Bias and Trials Stopped Early for Benefit

Edward L. Korn, PhD; Boris Freidlin, PhD; Margaret Mooney, MD
JAMA. 2010;304(2):156-159. doi:10.1001/jama.2010.932.
Text Size: A A A
Published online

Extract

To the Editor: Dr Bassler and colleagues1 suggested that stopping rules for clinical trials may not satisfy an ethical obligation to future patients because they can substantially overestimate the treatment effect. Stopping a trial and releasing the information early allows current and future patients to benefit from new therapies as soon as possible. Furthermore, it allows the new treatments to be tested in combination therapies and in earlier stages of disease when their benefits may even be greater. In life-threatening diseases such as cancer, these benefits outweigh not knowing precisely how efficacious the new treatment is. The number of events required for convincing evidence of benefit that is sufficient for early stopping should be prespecified in the protocol and derived with consideration of the disease and treatment being tested.

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

July 14, 2010
Scott M. Berry, PhD; Bradley P. Carlin, PhD; Jason Connor, PhD
JAMA. 2010;304(2):156-159. doi:10.1001/jama.2010.930.
July 14, 2010
Steven Goodman, MD, MHS, PhD; Donald Berry, PhD; Janet Wittes, PhD
JAMA. 2010;304(2):156-159. doi:10.1001/jama.2010.931.
July 14, 2010
Susan S. Ellenberg, PhD; David L. DeMets, PhD; Thomas R. Fleming, PhD
JAMA. 2010;304(2):156-159. doi:10.1001/jama.2010.933.
July 14, 2010
Gordon H. Guyatt, MD, MSc; Dirk Bassler, MD, MSc; Victor M. Montori, MD, MSc
JAMA. 2010;304(2):156-159. doi:10.1001/jama.2010.934.
CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 9

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();